NCT01357161View on ClinicalTrials.gov

A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)

PHASE2CompletedINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

July 26, 2011

Primary Completion Date

August 8, 2016

Study Completion Date

August 8, 2016

Conditions
Ovarian Cancer
Interventions
DRUG

adavosertib

Adavosertib capsules, orally, twice a day (BID) for a total of 5 doses starting on Day 1 of each 3-week cycle

DRUG

Placebo

placebo to adavosertib, capsule, orally, BID for a total of 5 doses, starting on Day 1 of each 3-week cycle

DRUG

paclitaxel

paclitaxel, intravenous (IV) infusion on Day 1 of each 3-week cycle

DRUG

carboplatin

carboplatin, IV infusion on Day 1 of each 3-week cycle

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01357161 - A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) | Biotech Hunter | Biotech Hunter